Drugs / KUP-101A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07600476 | Apr 2026 → Dec 2028 expected | cutaneous melanoma, cutaneous neuroendocrine carcinoma, mucosal melanoma, skin basal cell carcinoma +1 | Kupando GmbH | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KUP-101A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07600476 ↗ |
| Route | Intravenous | “Intravenous infusion of KUP-101A” NCT07600476 ↗ |